Michael Howell

Michael Howell is the Chief Scientific Officer at Zura Bio Limited, where he specializes in drug discovery, translational science, clinical biomarkers, and personalized medicine. He is also a Board Member and Scientific Advisor at Amytrx Therapeutics, Inc., Galileo Biosystems, and Mountaineer Biosciences, Inc. Previously, he served as the Chief Scientific Officer at DermTech, revolutionizing dermatology with innovative technology. Michael has a strong background in translational research and has held various scientific positions at companies like Incyte and MedImmune. He began his career in academia as an Assistant Professor at the National Jewish Medical and Research Center. Michael holds a Ph.D. in Microbiology and Immunology from West Virginia University School of Medicine and a B.S. in Biology and Chemistry from Messiah University.